AUTHOR=van Leeuwen Roeland B. , Colijn Carla , van Esch Babette F. , Schermer Tjard R. TITLE=Benign Recurrent Vertigo: The Course of Vertigo Attacks Compared to Patients With Menière's Disease and Vestibular Migraine JOURNAL=Frontiers in Neurology VOLUME=13 YEAR=2022 URL=https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2022.817812 DOI=10.3389/fneur.2022.817812 ISSN=1664-2295 ABSTRACT=Objective

To explore the course of vertigo attacks in patients with benign recurrent vertigo (BRV) as compared to patients with Menière's disease (MD) and vestibular migraine (VM).

Study design

Prospective cohort study.

Setting

Tertiary referral center.

Patients

Adult patients who visited the Apeldoorn Dizziness Center between January 2015 and November 2016 and who were diagnosed with BRV, VM or MD. During 3 years participants were contacted every 6 months by telephone to complete a study-specific questionnaire.

Main Outcome Measures

Vertigo attack frequency, use of medication, and Hospital Anxiety and Depression Scale (HADS).

Results

The study population (n = 121) consisted of 44 patients with BRV, 34 with VM, and 43 with MD. For the total follow-up period no statistically significant differences between the three diagnosis groups were observed for being attack-free in the past 6 months: OR = 0.86 (95% CI 0.34–2.17; p = 0.745) for VM and OR = 1.06 (95% CI 0.44–2.51; p = 0.902) for MD, compared to BRV. Overall, 19 patients (43.2%) with BRV, 13 (38.2%) with VM, and 35 (81.0%) with MD used medication to prevent vertigo attacks at any point during their 3-year follow-up. Throughout the observation period patients with MD showed an average of 3.37 points (95% CI 0.68–6.07; p = 0.014) higher HADS scores relative to patients with BRV.

Conclusion

The course of vertigo attacks was rather favorable in the three groups, as 67–70% of the patients were free of vertigo attacks after 3 years of follow-up. The course of disease in patients with BRV was not distinctive from patients with MD and VM. We assume that BRV is a mild or incomplete variant of VM and MD, rather than a separate disease entity with distinct pathognomonic features.